Awake Labs is committed to improving the lives of individuals with mental health disorders. Our first product is Reveal, a wearable device to measure anxiety for the 1 in 68 individuals with Autism Spectrum Disorders, in order to measure and track anxiety to empower families to understand behaviour and prevent meltdowns.
1 in 68 individuals in North America have an Autism Spectrum Disorder (ASD), which contributes to $56bn spent annually on non-medical costs each year. Reveal provides biometric analytics to help individuals with Autism Spectrum Disorders decrease anxiety and prevent behaviour meltdowns. 85% of individuals with ASDs will require continued support throughout their entire lives. 90% of individuals on the autism spectrum are unemployed or underemployed. We’re creating Reveal to help increase focus and learning in the classroom, to help with early intervention for increased independence, and to improve transition to the workforce.
Anxiety is like silent suffering. Autistic individuals often have difficulty relating to, and communicating their anxiety. Often, the only way to project anxiety to the people who care for them is through aggression, withdrawal, or self-injury. As many as 80% of children on the autism spectrum have anxiety that limits their potential to engage with the world and compromises their long term independence.
Reveal is a wearable device that measures the 3 leading physiological indicators of stress and anxiety in real-time in order to predict when a meltdown is about to happen, notify a parent of caregiver on their smartphone, so they can intervene and prevent the meltdown. For the first time, caregivers can have quantified datato better inform their care and maximize their
Currently, 1 in 68 individuals in North America have an Autism Spectrum Disorder, with a growing prevalence rate of 7% per year. Parents spend between $60,000-$75,000 each year on non-medical costs and the lifetime cost of autism is estimated to be between $5 and $8 million. Reveal can also be used for clinical stress and anxiety ($4.8b market), dementia ($8b market) and PTSD ($5.5bmarket), among others.